J L Blum
Affiliation: US Oncology
Blum J, Savin M, Edelman G, Pippen J, Robert N, Geister B, et al
. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer. 2007;7:850-6 pubmed publisher
..Survival of patients with SD > or = 16 weeks was similar to that of responders. ..
Blum J, GonÃ§alves A, Efrat N, Debled M, Conte P, Richards P, et al
. A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2016;155:295-302 pubmed publisher
..Single-agent trabectedin is well tolerated in aggressive MBC and has moderate activity in HER2-overexpressing tumors. Further studies are warranted to evaluate trabectedin combined with HER2-targeted treatments in this subtype. ..
Ghouadni A, Delaloge S, Lardelli P, Kahatt C, Byrski T, Blum J, et al
. Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial. Breast. 2017;34:18-23 pubmed publisher
..7 vs. 2.5 months). Trabectedin was well tolerated in both patient subtypes. In conclusion, trabectedin showed higher antitumor activity in relapsed MBC patients with germline BRCA2 mutations than in those with BRCA1 mutations. ..
Bunnell A, Garby C, Pearson E, Walker S, Panos L, Blum J. The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program. J Genet Couns. 2017;26:105-112 pubmed publisher
..Our findings suggest that there is clinical utility of panels that include genes of unknown to moderate penetrance. ..
Pearson E, Nair A, Daoud Y, Blum J. The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy. Breast Cancer Res Treat. 2017;162:59-67 pubmed publisher